Leerink Partners Maintains Buy Rating for Akebia Therapeutics with $7 Price Target

Reported about 9 hours ago

Leerink Partners has reiterated a Buy rating for Akebia Therapeutics (NASDAQ:AKBA), setting a price target of $7. The analyst highlights the company's potential for growth, particularly with its product Vafseo, which addresses anemia in chronic kidney disease dialysis patients. The upcoming Phase 3 VALOR trial is expected to further enhance the company's market opportunities.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis